Clinical Trials Browser

Phase 2 × Recurrent Uterine Corpus Carcinoma × Gefitinib × Clear all

NCT00027690 2019-07-23

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Phase 2 Completed

Recurrent Uterine Corpus Carcinoma